SUCRALFATE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Sucralfate, and what generic alternatives are available?
Sucralfate is a drug marketed by Abon Pharms Llc, Amneal, Hikma, Mylan, Pd Partners, Strides Pharma, Vistapharm Llc, Amneal Pharms, Nostrum Labs Inc, Teva, and Zydus Lifesciences. and is included in eleven NDAs.
The generic ingredient in SUCRALFATE is sucralfate. There are fourteen drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the sucralfate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sucralfate
A generic version of SUCRALFATE was approved as sucralfate by TEVA on March 29th, 1996.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SUCRALFATE?
- What are the global sales for SUCRALFATE?
- What is Average Wholesale Price for SUCRALFATE?
Summary for SUCRALFATE
| US Patents: | 0 |
| Applicants: | 11 |
| NDAs: | 11 |
| Finished Product Suppliers / Packagers: | 35 |
| Clinical Trials: | 25 |
| Drug Prices: | Drug price information for SUCRALFATE |
| Drug Sales Revenues: | Drug sales revenues for SUCRALFATE |
| What excipients (inactive ingredients) are in SUCRALFATE? | SUCRALFATE excipients list |
| DailyMed Link: | SUCRALFATE at DailyMed |
See drug prices for SUCRALFATE
Recent Clinical Trials for SUCRALFATE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| National Cheng-Kung University Hospital | N/A |
| National Cheng-Kung University Hospital | Phase 1 |
| Memorial Sloan Kettering Cancer Center | Phase 2 |
Pharmacology for SUCRALFATE
| Drug Class | Aluminum Complex |
Medical Subject Heading (MeSH) Categories for SUCRALFATE
Anatomical Therapeutic Chemical (ATC) Classes for SUCRALFATE
US Patents and Regulatory Information for SUCRALFATE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abon Pharms Llc | SUCRALFATE | sucralfate | SUSPENSION;ORAL | 216726-001 | Mar 21, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Vistapharm Llc | SUCRALFATE | sucralfate | SUSPENSION;ORAL | 211884-001 | Mar 15, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Mylan | SUCRALFATE | sucralfate | SUSPENSION;ORAL | 212913-001 | Sep 12, 2022 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
